Abstract Details

Title The Free and Cued Selective Reminding Test Predicts Alzheimer’s Disease Neuropathology

Topic Aging, Dementia, and Behavioral Neurology

Presentation(s) P4 - Poster Session 4 (5:30 PM-6:30 PM)

Poster/Presentation
Number 9-026

Objective To use performance on the picture version of the Free and Cued Selective Reminding Test with Immediate Recall (pFCSRT+IR) to predict Alzheimer’s Disease (AD) neuropathology defined by Braak stage.

Background The pFCSRT+IR is a widely-used episodic memory test that has participants identify items in response to category cues in the study phase. Following free recall (FR) in the test phase, category cues are presented to assess cued recall for items not retrieved by FR. Total recall (TR) is the sum of FR and cued recall. FR and TR have been shown to identify prevalent dementia, incident dementia and AD, amnestic mild cognitive impairment (aMCI) and to be associated with AD biomarkers.

Design/Methods 119 participants from the prospective Einstein Aging Study clinicopathologic series were staged using the methods of Braak and Braak. The FR and TR scores from the test administration closest to death were used to predict AD neuropathology as defined by a Braak stage of IV or greater. Receiver operating characteristic (ROC) analyses were used to assess FR and TR as screens for AD neuropathology. Youden’s index was used to select optimal cut scores.

Results The post-mortem sample had a mean age at death of 87, 60% were female and 27% had AD neuropathology. ROC analysis showed that both TR and FR predicted AD neuropathology with AUCs of 0.71 and 0.68 respectively. The AUC was not materially affected by adjustments for sex, education, age at death, or interval between last assessment and death for TR ( 0.72) or FR (0.70). The optimal cut score for TR was 43 (sen=0.69/spec=0.74), yielding an odds ratio of 8.1 (95% CI: 2.9,22.6). The optimal cut score for FR was 21 (sen=0.78/spec=0.55) yielding an odds ratio of 5.1 (95% CI: 1.8,14.5).

Conclusions Both FR and TR predict AD neuropathology.

Authors/Disclosures
Ellen H. Grober, PhD PRESENTER	No disclosure on file
Richard B. Lipton, MD, FAAN (Albert Einstein College of Medicine)	Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Allergan/Abbvie. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Amgen. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biohaven. Dr. Lipton has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Eli Lilly. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Lundbeck. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for GlaxoSmithKline. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Teva. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Vedanta. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Grifols. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Pfizer. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Axon. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Satsuma. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cool Tech. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BDSI. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Linpharma. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Axsome. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Clexio. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Shiratronics. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Allergan/Abbvie. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biohaven. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli Lilly. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. Dr. Lipton has or had stock in Biohaven.Dr. Lipton has or had stock in Manistee.Dr. Lipton has or had stock in Axon.Dr. Lipton has or had stock in CoolTech. The institution of Dr. Lipton has received research support from Teva. The institution of Dr. Lipton has received research support from Amgen. The institution of Dr. Lipton has received research support from Allergan/Abbvie. The institution of Dr. Lipton has received research support from Gammacore. The institution of Dr. Lipton has received research support from Axsome. The institution of Dr. Lipton has received research support from Charleston Labs. The institution of Dr. Lipton has received research support from Eli Lilly. The institution of Dr. Lipton has received research support from Satsuma. The institution of Dr. Lipton has received research support from NIH . The institution of Dr. Lipton has received research support from Veterans Administration. Dr. Lipton has received publishing royalties from a publication relating to health care.
	No disclosure on file

��ɫ��

��ɫ��